Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
|
|
- Dayna Benson
- 5 years ago
- Views:
Transcription
1 Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria A: Alogliptin 6.25mg, Januvia 25mg, Nesina 6.25mg, Onglyza 2.5mg and Tradjenta 5mg Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria DPP-4 Inhibitor Criteria B: Alogliptin 12.5mg, Januvia 50mg and Nesina 12.5mg Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria April 3, 2018 Copyright Health Information Designs, LLC 1
2 DPP-4 Inhibitor Criteria C: Alogliptin 25mg, Januvia 100mg, Nesina 25mg and Onglyza 5mg Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria te: Click the hyperlink to navigate directly to that section. DPP-4 Inhibitor Combination Agents Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria te: Click the hyperlink to navigate directly to that section. Revision tes Annual review by staff Removed ICD-9 codes Added GCNs for alogliptin, Nesina, Tradjenta, Onglyza and the DPP-4 inhibitor combination products Added logic and logic diagram for combination products April 3, 2018 Copyright Health Information Designs, LLC 2
3 Criteria Set A Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN ALOGLIPTIN 6.25 MG TABLET JANUVIA 25 MG TABLET NESINA 6.25 MG TABLET ONGLYZA 2.5 MG TABLET TRADJENTA 5 MG TABLET April 3, 2018 Copyright Health Information Designs, LLC 3
4 Criteria Set A Clinical Criteria Logic 1. Is the client greater than or equal to () 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of type II diabetes in the past 730 days? [ ] (Go to #3) [ ] (Deny) 3. Are the requested units less than or equal to () 1 tablet per day? [ ] (Approve 365 days) [ ] (Deny) April 3, 2018 Copyright Health Information Designs, LLC 4
5 Criteria Set A Clinical Criteria Logic Diagram Step 1 Is the client 18 years of age? Step 2 Does the client have a diagnosis of type II diabetes in the past 730 days? Step 3 Are the requested units 1 tablet per day? Approve Request (365 days) April 3, 2018 Copyright Health Information Designs, LLC 5
6 Criteria Set A Clinical Criteria Supporting Tables ICD-10 Code E1100 E1101 E1121 E1122 E1129 E11311 E11319 E11321 E11329 E11331 E11339 E11341 E11349 E11351 E11359 E1136 E1139 E1140 E1141 E1142 E1143 Description Step 2 (diagnosis of type II diabetes) Required diagnosis: 1 Look back timeframe: 730 days TYPE 2 DIABETES MELLITUS WITH HYPEROSMOLARITY WITHOUT NONKETOTIC HYPERGLYCEMIC-HYPEROSMOLAR COMA (NKHHC) TYPE 2 DIABETES MELLITUS WITH HYPEROSMOLARITY WITH COMA TYPE 2 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY TYPE 2 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC KIDNEY COMPLICATION TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITH MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA TYPE 2 DIABETES MELLITUS WITH DIABETIC CATARACT TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC OPHTHALMIC COMPLICATION TYPE 2 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED TYPE 2 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY TYPE 2 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY TYPE 2 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY April 3, 2018 Copyright Health Information Designs, LLC 6
7 ICD-10 Code E1144 E1149 E1151 E1152 E1159 E11610 E11618 E11620 E11621 E11622 E11628 E11630 E11638 E11641 E11649 E1165 E1169 E118 E119 Description Step 2 (diagnosis of type II diabetes) Required diagnosis: 1 Look back timeframe: 730 days TYPE 2 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION TYPE 2 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITHOUT GANGRENE TYPE 2 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITH GANGRENE TYPE 2 DIABETES MELLITUS WITH OTHER CIRCULATORY COMPLICATIONS TYPE 2 DIABETES MELLITUS WITH DIABETIC NEUROPATHIC ARTHROPATHY TYPE 2 DIABETES MELLITUS WITH OTHER DIABETIC ARTHROPATHY TYPE 2 DIABETES MELLITUS WITH DIABETIC DERMATITIS TYPE 2 DIABETES MELLITUS WITH FOOT ULCER TYPE 2 DIABETES MELLITUS WITH OTHER SKIN ULCER TYPE 2 DIABETES MELLITUS WITH OTHER SKIN COMPLICATIONS TYPE 2 DIABETES MELLITUS WITH PERIODONTAL DISEASE TYPE 2 DIABETES MELLITUS WITH OTHER ORAL COMPLICATIONS TYPE 2 DIABETES MELLITUS WITH HYPOGLYCEMIA WITH COMA TYPE 2 DIABETES MELLITUS WITH HYPOGLYCEMIA WITHOUT COMA TYPE 2 DIABETES MELLITUS WITH HYPERGLYCEMIA TYPE 2 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATION TYPE 2 DIABETES MELLITUS WITH UNSPECIFIED COMPLICATIONS TYPE 2 DIABETES MELLITUS WITHOUT COMPLICATIONS April 3, 2018 Copyright Health Information Designs, LLC 7
8 Criteria Set B Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN ALOGLIPTIN 12.5 MG TABLET JANUVIA 50 MG TABLET NESINA 12.5 MG TABLET April 3, 2018 Copyright Health Information Designs, LLC 8
9 Criteria Set B Clinical Criteria Logic 1. Is the client greater than or equal to () 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of type II diabetes in the past 730 days? [ ] (Go to #3) [ ] (Deny) 3. Does this client have a diagnosis of severe renal failure or ESRD in the last 730 days? [ ] (Deny) [ ] (Go to #4) 4. Are the requested units less than or equal to () 1 tablet per day? [ ] (Approve 365 days) [ ] (Deny) April 3, 2018 Copyright Health Information Designs, LLC 9
10 Criteria Set B Clinical Criteria Logic Diagram Step 1 Is the client 18 years of age? Step 2 Does the client have a diagnosis of type II diabetes in the past 730 days? Step 3 Step 4 Does the client have a diagnosis of severe renal failure or ESRD in the last 730 days? Are the requested units 1 tablet per day? Approve Request (365 days) April 3, 2018 Copyright Health Information Designs, LLC 10
11 Criteria Set B Clinical Criteria Supporting Tables Step 2 (diagnosis of type II diabetes) Required diagnosis: 1 Look back timeframe: 730 days For the list of type II diabetes diagnosis codes that pertain to this step, see the Type II Diabetes Diagnoses table in the previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. Step 3 (diagnosis of severe renal failure or ESRD) Required diagnosis: 1 Look back timeframe: 730 days ICD-10 Code Description N184 CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) N185 CHRONIC KIDNEY DISEASE, STAGE 5 N186 END STAGE RENAL DISEASE April 3, 2018 Copyright Health Information Designs, LLC 11
12 Criteria Set C Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN ALOGLIPTIN 25 MG TABLET JANUVIA 100 MG TABLET NESINA 25 MG TABLET ONGLYZA 5 MG TABLET April 3, 2018 Copyright Health Information Designs, LLC 12
13 Criteria Set C Clinical Criteria Logic 1. Is the client greater than or equal to () 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of type II diabetes in the past 730 days? [ ] (Go to #3) [ ] (Deny) 3. Does the client have a diagnosis of moderate renal failure in the last 730 days? [ ] (Deny) [ ] (Go to #4) 4. Does the client have a diagnosis of severe renal failure or ESRD in the last 730 days? [ ] (Deny) [ ] (Go to #5) 5. Is the dose less than or equal to () 1 tablet per day? [ ] (Approve 365 days) [ ] (Deny) April 3, 2018 Copyright Health Information Designs, LLC 13
14 Criteria Set C Clinical Criteria Logic Diagram Step 1 Is the client 18 years of age? Step 2 Does the client have a diagnosis of type II diabetes in the last 365 days? Step 3 Does the client have a diagnosis of moderate renal failure in the last 730 days? Step 4 Does the client have a diagnosis of severe renal failure or ESRD in the last 730 days? Step 5 Is the dose 1 tablet per day? Approve Request (365 days) April 3, 2018 Copyright Health Information Designs, LLC 14
15 Criteria Set C Clinical Criteria Supporting Tables Step 2 (diagnosis of type II diabetes) Required diagnosis: 1 Look back timeframe: 730 days For the list of type II diabetes diagnosis codes that pertain to this step, see the Type II Diabetes Diagnoses table in a previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. ICD-10 Code N183 Step 3 (diagnosis of moderate renal failure) Required diagnosis: 1 Look back timeframe: 730 days Description CHRONIC KIDNEY DISEASE, STAGE 3 (MODERATE) Step 4 (diagnosis of severe renal failure or ESRD) Required diagnosis: 1 Look back timeframe: 730 days For the list of type II diabetes diagnosis codes that pertain to this step, see the Severe Renal Failure or ESRD Diagnoses table in a previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. April 3, 2018 Copyright Health Information Designs, LLC 15
16 Criteria Set D Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN ALOGLIPTIN-METFORMIN ALOGLIPTIN-METFORMIN ALOGLIPTIN-PIOGLIT MG ALOGLIPTIN-PIOGLIT MG ALOGLIPTIN-PIOGLIT MG ALOGLIPTIN-PIOGLIT MG ALOGLIPTIN-PIOGLIT MG ALOGLIPTIN-PIOGLIT MG GLYXAMBI 10-5 MG TABLET GLYXAMBI 25-5 MG TABLET JANUMET MG TABLET JANUMET MG TABLET JANUMET XR MG TABLET JANUMET XR MG TABLET JANUMET XR MG TABLET JENTADUETO MG TAB JENTADUETO MG TAB JENTADUETO MG TAB JENTADUETO XR MG TAB JENTADUETO XR MG TAB KAZANO MG TABLET KAZANO MG TABLET KOMBIGLYZE XR MG TAB KOMBIGLYZE XR MG TAB KOMBIGLYZE XR MG TABLET OSENI MG TABLET OSENI MG TABLET OSENI MG TABLET OSENI MG TABLET OSENI MG TABLET OSENI MG TABLET QTERN 10-5 MG TABLET STEGLUJAN MG TABLET STEGLUJAN MG TABLET April 3, 2018 Copyright Health Information Designs, LLC 16
17 Criteria Set D Clinical Criteria Logic 1. Is the client greater than or equal to () 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of type II diabetes in the last 730 days? [ ] (Go to #3) [ ] (Deny) 3. Does the client have a diagnosis of severe renal failure or ESRD in the last 730 days? [ ] (Deny) [ ] (Approve 365 days) April 3, 2018 Copyright Health Information Designs, LLC 17
18 Criteria Set D Clinical Criteria Logic Diagram Step 1 Step 2 Step 3 Is the client 18 years of age? Does the client have a diagnosis of T2DM in the last 730 days? Does the client have a diagnosis of severe renal failure or ESRD in the last 730 days? Approve Request (365 days) April 3, 2018 Copyright Health Information Designs, LLC 18
19 Criteria Set D Clinical Criteria Supporting Tables Step 2 (diagnosis of type II diabetes) Required diagnosis: 1 Look back timeframe: 730 days For the list of type II diabetes diagnosis codes that pertain to this step, see the Type II Diabetes Diagnoses table in a previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. Step 3 (diagnosis of severe renal failure or ESRD) Required diagnosis: 1 Look back timeframe: 730 days For the list of type II diabetes diagnosis codes that pertain to this step, see the Severe Renal Failure or ESRD Diagnoses table in a previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. April 3, 2018 Copyright Health Information Designs, LLC 19
20 Clinical Criteria References ICD-10-CM Diagnosis Codes Available at Accessed on April 3, American Medical Association data files ICD-10-CM Diagnosis Codes. Available at 3. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; Available at Accessed on April 3, Micromedex [online database]. Available at Accessed on April 3, American Diabetes Association. Standards of Medical Care in Diabetes Diabetes Care. January 2017;40(1):S1-S Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm 2017 Executive Summary. Endocr Pract Feb;23(2): Januvia Prescribing Information. Whitehouse Station, NJ. Merck Sharp & Dohme Corp. February Nesina Prescribing Information. Deerfield, IL. Takeda Pharmaceuticals. December Kazano Prescribing Information. Deerfield, IL. Takeda Pharmaceuticals. February Oseni Prescribing Information. Deerfield, IL. Takeda Pharmaceuticals. December Tradjenta Prescribing Information. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc. August Onglyza Prescribing Information. Wilmington, DE. AstraZeneca Pharmaceuticals LP. February Jentadueto Prescribing Information. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc. August Jentadueto XR Prescribing Information. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc. August April 3, 2018 Copyright Health Information Designs, LLC 20
21 15.Kombiglyze XR Prescribing Information. Wilmington, DE. AstraZeneca Pharmaceuticals LP. February Janumet Prescribing Information. Whitehouse Station, NJ. Merck Sharp & Dohme Corp. February Janumet XR Prescribing Information. Whitehouse Station, NJ. Merck Sharp & Dohme Corp. February Glyxambi Prescribing Information. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc. December Qtern Prescribing Information. Wilmington, DE. AstraZeneca Pharmaceuticals LP. February Steglujan Prescribing Information. Whitehouse Station, NJ. Merck Sharp & Dohme Corp. February April 3, 2018 Copyright Health Information Designs, LLC 21
22 Publication History The Publication History records the publication iterations and revisions to this document. tes for the most current revision are also provided in the Revision tes on the first page of this document. Publication Date tes 01/31/2011 Initial publication and posting to website 05/11/2012 Separated sitagliptin (Januvia) into three sections: one for 25mg, one for 50mg, and one for 100mg Added a new section to specify the drugs requiring prior authorization for each strength of sitagliptin (Januvia) In each Clinical Edit Supporting Tables section, revised tables to specify the diagnosis codes pertinent to steps 2, 4, and 5 of the logic diagrams 07/18/2012 Removed steps 4 and 5 regarding moderate to severe renal failure for sitagliptin (Januvia) 25mg to reflect rules in system Changed step 3 to deny with a history of severe renal failure or ESRD for sitagliptin (Januvia) 50mg to reflect rules in system 04/03/2015 Updated to include ICD-10s 04/03/2018 Annual review by staff Removed ICD-9 codes Added GCNs for alogliptin, Nesina, Tradjenta, Onglyza and the DPP-4 inhibitor combination products Added logic and logic diagram for combination products April 3, 2018 Copyright Health Information Designs, LLC 22
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents This criteria was recommended for review by an MCO to ensure appropriate
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Thiazolidinediones Clinical Edit Information Included in this Document Thiazolidinediones Drugs requiring prior authorization: the
More informationSitagliptin (Januvia)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document 25mg Drugs requiring prior authorization: the list of drugs requiring prior
More informationHypoglycemics, Lantus Insulin
Texas Prior Authorization Program PDL Edit Criteria Drug/Drug Class Hypoglycemics, Lantus Insulin Information Included in this Document Hypoglycemics, Lantus Insulin Drugs requiring prior authorization:
More informationGlucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Superior HealthPlan follows the guidance of the Texas Vendor Drug
More informationByetta (Exenatide Injection)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationVictoza (Liraglutide) Solution for Injection
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationLidoderm (Lidocaine) Patch
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationDiclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class, Diclofenac 1.5% and 2% Topical Solution This criteria was recommended for review by an MCO to ensure appropriate and safe utilization
More informationAmitiza (Lubiprostone)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Provigil (Modafinil) Drugs requiring prior authorization: the list of drugs
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3086-5 Program Step Therapy Diabetes Medications - SGLT2 Inhibitors Medication Farxiga (dapagliflozin)*, Glyxambi (empagliflozin/linagliptan),
More informationAgents for the Treatment of Hepatitis C
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationTherapeutic Shoes for Diabetics
Last Review Date: August 11, 2017 Number: MG.MM.DM.03bC8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationAnthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are
page 1 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association.
Insulin Pump Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association. Title: Insulin Pump Professional Original Effective Date: January 1, 1999 Revision Date(s): June
More informationGlycated Hemoglobin/Glycated Protein
190.21 - Glycated Hemoglobin/Glycated Protein The management of diabetes mellitus requires regular determinations of blood glucose levels. Glycated hemoglobin/protein levels are used to assess long-term
More informationDipeptidyl Peptidase-4 (DPP-4) Inhibitors, DPP-4 Inhibitor Combination Drugs, Cycloset (bromocriptine)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, DPP-4 Inhibitor Combination Drugs, Cycloset (bromocriptine) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and
More informationPrior Authorization Neurontin (gabapentin) 2016
Drugs Requiring Prior Authorization Label Name GCN GABAPENTIN 100 MG CAPSULE 00780 GABAPENTIN 300 MG CAPSULE 00781 GABAPENTIN 400 MG CAPSULE 00782 GABAPENTIN 250 MG/5 ML SOLN 13235 GABAPENTIN 600 MG TABLET
More informationFentanyl Agents Clinical Edit Criteria
Fentanyl Agents Clinical Edit Criteria Drug/Drug Class: Fentanyl Agents Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. Superior has adjusted
More informationTexas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Clinical Information Included in this
More informationMethylnaltrexone Bromide (Relistor)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Aldurazyme Adagen Carbaglu Ceprotin Elaprase Fabrazyme Lumizyme Naglazyme Orfandin Ravicti Vimizim Note: Click the hyperlink to navigate
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationrevolutionehr.com 2019 Clinical Quality Measure Scoring Guide
revolutionehr.com 2019 Clinical Quality Measure Scoring Guide Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These
More informationContractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information
Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationFee for Service Pay for Performance Program Guidelines Program Year
Fee for Service Pay for Performance Program Guidelines 2018 Program Year 2 General Program Guidelines Table of Contents General Program Guidelines... 4 Program Overview... 4 Provider Participation Eligibility...
More informationFormulary Medical Necessity Program
BENEFIT APPLICATION Formulary Medical Necessity Program DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationTexas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More information2017 Clinical Quality Measures
2017 Clinical Quality Measures Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These statistics involve data related
More informationMedical Policy Original Effective Date: April 1999 Revised Date: 07/25/2018 Page 1 of 36
Page 1 of 36 Content This includes the following items: 1. Home Blood Glucose Monitors: Prior Authorization is not required. 2. Insulin pumps, cartridges and reservoirs. Prior Authorization is not required.
More informationSample. V18.2 Special Report: Postpartum Readmissions What Drives Your Rate?
V18.2 Special Report: Postpartum Readmissions What Drives Your Rate? INTRODUCTION In FY 2013, the Center for Medicare and Medicaid Services (CMS) began the Hospital Readmission Reduction Program (HRRP)
More informationThiazolidinedione Step Therapy Program
Thiazolidinedione Step Therapy Program Policy Number: 5.01.580 Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationCOMPREHENSIVE DIABETES CARE
COMPREHENSIVE DIABETES CARE APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What screening should be done? HbA1c Eye Exam Blood Pressure Nephropathy
More informationTexas Prior Authorization Program Clinical Criteria. Allergen Extracts
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Oralair (Mixed Grass Pollens Allergen Extract)) Drugs requiring prior authorization: the
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAsthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Aldara 5% Cream Drugs requiring prior authorization: the list of drugs requiring
More informationInjectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
More informationCoding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medicaid Managed Care December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease in the amount of insulin
More informationMedical Policy Original Effective Date: Revised Date: Page 1 of 23
Page 1 of 23 Disclaimer Description Coverage Determination Refer to the member s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on all plans or the plan
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A
Local Coverage Determination (LCD): Laparoscopic Sleeve Gastrectomy for Severe Obesity (L34238) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
More informationProvider Bulletin December 2018 Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medi-Cal Managed Care L. A. Care Provider Bulletin December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease
More informationInformation for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets
Information for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets This list does not imply that the products on this chart are interchangeable
More informationPrior Authorization Flexeril/Amrix (cyclobenzaprine) 2017
Drugs Requiring Prior Authorization Label Name GCN AMRIX ER 15 MG CAPSULE 97959 AMRIX ER 30 MG CAPSULE 97960 CYCLOBENZAPRINE 10 MG TABLET 18020 CYCLOBENZAPRINE 5 MG TABLET 12805 CYCLOBENZAPRINE 7.5 MG
More informationOutcomes in Diabetic Macular Edema (DME) in Patients Who Used Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the VISTA and VIVID trials
Outcomes in Diabetic Macular Edema (DME) in Patients Who Used Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the VISTA and VIVID trials Ehsan Rahimy, MD 1 ; Keith Baker, MD 2 ; Desmond Thompson,
More informationMedical Policy Routine Foot Care and Debridement of Toenails
Medical Policy Routine Foot Care and Debridement of Toenails Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description Endnotes Authorization
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 08/22/2018 Effective Date: 08/22/2018 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,
More informationDeaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationAccepted. Original Article. I-Ting Liu 1, Ru-Yi Huang 1,2, Cheuk-Kwan Sun 3,4,Chi-Wei Lin 1,2
E-Da Medical Journal 2017;4(4):10-18 Original Article The Prognosis and Healthcare Expenditure of Newly Diagnosed Diabetic Patients Are There Differences Between Family Physicians and the Internists? I-Ting
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 3/1/2012 Most Recent Review Date (Revised): 4/11/2018 Effective Date: 8/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationAgents for Cystic Fibrosis
Texas Prior Authorization Program Clinical Edit Criteria Clinical Edit Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior
More informationContractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information
FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective
More informationExpanded Fall Risk Factors, Locations of Data Extraction, and Coding. Diastolic blood pressure value (mmhg) Calculated body mass index
Appendix B Expanded Fall Risk Factors, Locations of Data Extraction, and Coding Factor Location Coding Blood pressure systolic Blood pressure diastolic Body mass index Systolic blood pressure value (mmhg)
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueCross BlueShield of WNY requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationDiabetes Mellitus. and coding the complications that can occur
Diabetes Mellitus and coding the complications that can occur As a coder.don t get stuck in neutral You have to keep moving forward with the new compliances and codes Diabetes Mellitus with. let s take
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationFlexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria
Flexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria Drug/Drug Class: Flexeril/Amrix (Cyclobenzaprine) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationBYSTOLIC. Products Affected Step 2: BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET. Details BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET
BYSTOLIC BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET authorization for a Step 2 drug may be given. Step 1 Drug(s): generic beta-blockers and/or combinations,
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationDiabetic Complications: Diagnosis, Documentation, Coding, and Compliance
Diabetic Complications: Diagnosis, Documentation, Coding, and Compliance Richard D. Pinson, MD, FACP, CCS Principal and Medical Director Pinson and Tang, LLC CDI Educators and Consultants Houston, TX 1
More informationThyroid Testing
190.22 - Thyroid Testing Thyroid function studies are used to delineate the presence or absence of hormonal abnormalities of the thyroid and pituitary glands. These abnormalities may be either primary
More informationDrugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Sodium-Glucose Co-Transpter 2 (SGLT2) Inhibits Reference Number: TCHP.PHAR.182 Effective Date: 07.01.18 Last Review Date: 04.13.18 Line of Business: Oregon Health Plan Revision Log See Imptant
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationICD-10-CM: The Sage Continues
ICD-10-CM: The Sage Continues UHIMA Kathy DeVault, MSL, RHIA, CCS, CCS-P, FAHIMA UASI Kathy.devault@uasisolutions.com Objectives Review quality documentation Discuss use of unspecified codes Discuss opportunities
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationFlexeril/Amrix (Cyclobenzaprine)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More information2 Master the ICD 10 Payment System to Prevent Revenue Losses
Master the ICD 10 Payment System to Prevent Revenue Losses Tricia A. Twombly BSN RN HCS D HCS O COS C CHCE AHIMA Approved ICD 10 CM Trainer Senior Director, DecisionHealth Chief Executive Officer, BMSC
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationClinical Policy Title: Artificial pancreas device system
Clinical Policy Title: Artificial pancreas device system Clinical Policy Number: 08.02.07 Effective Date: April 1, 2016 Initial Review Date: November 18, 2015 Most Recent Review Date: February 6, 2018
More information3/20/2017. CONNECTING THE LATEST GUIDANCE FY2017 FOR ICD-10 MATTERS Kyla D. Harrison, RN, BSN, HCS-D, COS-C Visiting Nurse Association of Kansas City
CONNECTING THE LATEST GUIDANCE FY2017 FOR ICD-10 MATTERS Kyla D. Harrison, RN, BSN, HCS-D, COS-C Visiting Nurse Association of Kansas City Coding needs met in many different ways: 1. Fulltime Coders HCS-D
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More information